Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.

NCT06434597 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT06434597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06434597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
July 17, 2024
Completion date
December 31, 2026
Enrollment
60 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract or colorectal cancer with her2-positive/mutated